GHRP-2, also called pralmorelin, is a synthetic growth hormone secretagogue: a six-residue peptide that prompts the pituitary to release the body's own growth hormone instead of supplying the hormone directly. It binds the GHS-R1a receptor, the same one the stomach hormone ghrelin uses, and coaxes a physiological, pulse-shaped release that still passes through normal feedback controls. The published record describes this mechanism in detail, but GHRP-2 is classified as a research peptide and is not an approved therapeutic drug in most jurisdictions.
GHRP-2 (pralmorelin) is a synthetic hexapeptide that binds the GHS-R1a ghrelin receptor to trigger a pulse of the body's own growth hormone, and it is classified as a research peptide rather than an approved drug in most jurisdictions.
The active molecule is a short chain of just six amino acids, but almost every residue is chosen to defeat the enzymes that would otherwise destroy it. The published sequence uses D-configuration and non-natural amino acids such as 2-naphthylalanine, an engineering choice that gives the peptide enough metabolic stability to reach the pituitary after injection.
GHRP-2 is a synthetic hexapeptide of roughly 817 daltons whose D-configuration and non-proteinogenic residues resist enzymatic breakdown, placing it in the growth hormone secretagogue class rather than among growth hormones themselves.
The entire effect starts at one switch: the GHS-R1a receptor sitting on pituitary somatotrophs and hypothalamic neurons. GHRP-2 binds it as an agonist and sets off a second-messenger cascade that ends in a burst of stored growth hormone, and because that burst draws on a readily releasable pool, the output is a sharp pulse rather than a steady trickle. Too-frequent exposure desensitizes the receptor, one reason spaced dosing preserves the response.
GHRP-2 agonizes the GHS-R1a receptor through a Gq-phospholipase C cascade that raises intracellular calcium, producing a sharp pulse of stored growth hormone rather than a steady release.
GHRP-2 works within the existing hypothalamic-pituitary axis rather than around it, which is why its action is called physiological. It presses on two points of the same circuit at once, lifting the growth hormone releasing hormone signal while easing off somatostatin, the natural brake. That dual action depends on a healthy gland stocked with releasable hormone; where somatotroph reserve is exhausted, the compound has less to work with.
GHRP-2 acts at both the hypothalamus, where it lifts growth hormone releasing hormone tone and blunts somatostatin, and the pituitary, where it directly stimulates somatotrophs, so a GHRH analog paired with it yields a larger pulse than either alone.
Although GHRP-2 mimics ghrelin at the shared receptor, it is a copy of neither of the body's natural growth hormone signals. It is far shorter than the 28-amino-acid ghrelin molecule and switches the receptor on without the octanoyl fatty-acid group ghrelin needs, and it works through an entirely different pathway than growth hormone releasing hormone. Those differences are exactly why GHRP-2 and a releasing-hormone analog complement rather than duplicate each other.
| Property | GHRP-2 | Native ghrelin | GHRH |
|---|---|---|---|
| Size | Hexapeptide (6 residues) | 28-amino-acid hormone | Larger, distinct peptide |
| Receptor | GHS-R1a | GHS-R1a (needs octanoyl group) | Own GHRH receptor |
| Signaling | Calcium / phospholipase C | Calcium / phospholipase C | Cyclic AMP |
| Appetite signal | Mild | Strong | Minimal |
| Functional window | Longer | Fades within minutes | Short |
GHRP-2 switches on the GHS-R1a receptor through a calcium-phospholipase C pathway like ghrelin but with milder appetite signaling, while growth hormone releasing hormone works through a separate receptor and cyclic AMP, which is why combining GHRP-2 with a releasing-hormone analog produces a larger pulse than either alone.
The growth hormone spike a dose produces is brief, but most of the lasting biology happens one step downstream through IGF-1. The released hormone reaches the liver and drives IGF-1 production, which carries the anabolic signaling over hours and days rather than minutes. There is a tradeoff worth noting: growth hormone is counter-regulatory to insulin, so pronounced or sustained elevation can nudge blood glucose upward and blunt insulin sensitivity.
A GHRP-2 dose produces a growth hormone surge that peaks within minutes and fades within an hour or two, while the IGF-1 it drives in the liver sustains protein synthesis, connective-tissue repair, and fat mobilization over hours to days.
GHRP-2 is not perfectly selective for growth hormone, and its shared use of the ghrelin receptor means it reaches into several other hormonal systems. The best-documented off-target effects are modest, short-lived rises in cortisol and prolactin at moderate doses, but they climb with the dose, which is a central reason pushing the dose higher trades diminishing growth hormone returns for a rising side-effect load.
Because GHRP-2 shares the ghrelin receptor, moderate doses produce mild, transient rises in cortisol, ACTH, and prolactin plus increased appetite, and these off-target effects grow more pronounced as the dose climbs, yielding diminishing growth hormone returns.
GHRP-2 traces back to an accidental finding: in the late twentieth century, researchers chasing opioid-like enkephalin peptides noticed some of them provoked growth hormone release. That observation launched a deliberate design effort that produced the growth hormone releasing peptide family, and GHRP-2 emerged as a more potent, cleaner-signaling refinement of the earlier GHRP-6.
GHRP-2, or pralmorelin, was developed from enkephalin-derived observations into a refinement of GHRP-6 and saw formal use as a growth hormone stimulation test agent in at least one country, but it never gained broad therapeutic approval and remains a research peptide in most jurisdictions.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
